Asalyxa Bio, Inc., a biopharmaceutical startup developing nano-engineered, immune cell-targeted therapeutics, just announced the closing of an over-subscribed seed financing round totaling more than $2 million. The funding was led by Research Bridge Partners, co-led by ID Ventures, and included Michigan Rise Pre-Seed Fund III, BRCC of Western Michigan University, Ann Arbor Spark, Woodward Angels and other undisclosed investors. The funding will be used to move Asalyxa Bio’s lead development candidate, ASX-100, toward first-in-human clinical trials. We previously highlighted Asalyxa Bio’s early work on Cronicle as the company, led by Asalyxa Bio and holding company OrangeGrove Bio CEO Marc Appel, applied their technology to addressing Acute Respiratory Distress Syndrome caused by COVID-19 and other diseases.
Pocketnest, a new app for next-gen financial wellness used by top credit unions and companies like Cisco and Henry Ford, has experienced explosive growth over the past year after closing its Series A funding round in 2019. The Ann Arbor-based fintech startup was founded by financial advisor Jessica Willis just 12 months ago after realizing there was very little out there in the way of non-transactional financial wellness apps for Gen X and millennials who were looking for technology to ease communication with financial advisors and to glean accessible financial wellness education and advice. Now boasting 8 enterprise clients with 20% user growth month over month and 40% growth month over month from an enterprise standpoint, Pocketnest now works with the top 3 largest credit unions in the United States–Wright-Patt Credit Union, Lake Trust Credit Union, and MSU Federal Credit Union–and growing.